Evkeeza Evropska unija - italijanščina - EMA (European Medicines Agency)

evkeeza

ultragenyx germany gmbh - evinacumab - ipercolesterolemia - agenti modificanti i lipidi - evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (ldl-c) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (hofh).